Pharvaris N.V. Files 2025 Annual Report, Maintains Foreign Issuer Status

TL;DR

**Pharvaris N.V.'s 20-F filing is a procedural update, offering no immediate catalysts but confirming regulatory compliance for 2025.**

AI Summary

Pharvaris N.V. filed its 20-F for the period ending December 31, 2025, indicating its ongoing status as a foreign private issuer. The filing itself does not contain specific financial figures for revenue or net income, as it is a structural document outlining the company's annual report requirements. Key business changes or strategic outlooks are not detailed within the provided metadata, which focuses on the filing's technical aspects and company identification. Risks are implicitly tied to the nature of a pharmaceutical preparations company, but no specific risk factors or dollar amounts are extractable from the given information. The document confirms Pharvaris N.V.'s business address as J.H. Oortweg 21, 2333 CH Leiden, Netherlands, and its fiscal year end as December 31. The filing includes various exhibits such as EX-2.1, EX-8.1, and EX-11.1, which typically contain agreements, lists of subsidiaries, and codes of ethics, respectively, but their content is not summarized here. The company's CIK is 0001830487 and its SIC code is 2834 for Pharmaceutical Preparations.

Why It Matters

This 20-F filing confirms Pharvaris N.V.'s compliance with SEC reporting requirements as a foreign private issuer for the 2025 fiscal year. For investors, it signals continued transparency and adherence to regulatory standards, which is crucial for maintaining market confidence. While specific financial details are not provided in the metadata, the filing's existence indicates the company's operational continuity in the competitive pharmaceutical preparations sector. Employees and customers can infer stability from the company's ongoing regulatory compliance, suggesting a steady operational environment. The broader market gains clarity on Pharvaris's reporting schedule and legal standing.

Risk Assessment

Risk Level: low — The provided information is purely administrative, detailing the filing of a 20-F document by Pharvaris N.V. for the period ending December 31, 2025. There are no financial figures, operational updates, or specific risk factors mentioned that would indicate a 'medium' or 'high' risk level. The filing itself is a standard regulatory requirement, not an event that inherently introduces new risks.

Analyst Insight

Investors should view this filing as a routine compliance update, not a trigger for immediate action. Further due diligence on the full 20-F document is required to assess Pharvaris N.V.'s financial performance, operational risks, and strategic direction for the 2025 fiscal year. This metadata alone does not provide sufficient information for investment decisions.

Key Numbers

• 2025-12-31 — Fiscal Year End (The period covered by this 20-F report.)
• 2026-04-02 — Filing Date (When the 20-F was officially submitted to the SEC.)
• 0001830487 — CIK (Unique identifier for Pharvaris N.V. with the SEC.)
• 2834 — SIC Code (Industry classification for Pharmaceutical Preparations.)

Key Players & Entities

• Pharvaris N.V. (company) — Filer of 20-F
• SEC (regulator) — Securities and Exchange Commission
• 0001830487 (regulator) — CIK of Pharvaris N.V.
• 2025-12-31 (date) — Period of Report
• 2026-04-02 (date) — Filing Date
• J.H. Oortweg 21, 2333 CH Leiden, Netherlands (company) — Business Address of Pharvaris N.V.
• 31 (0)71 203 6410 (company) — Phone number of Pharvaris N.V.
• 2834 (company) — SIC code for Pharmaceutical Preparations

FAQ

Industry Context

Pharvaris N.V. operates in the pharmaceutical preparations industry, a sector characterized by significant research and development investment, stringent regulatory oversight, and long product development cycles. The industry is highly competitive, with companies striving to bring innovative therapies to market. Trends include a focus on specialized treatments, advancements in biotechnology, and evolving global healthcare policies.

Regulatory Implications

As a foreign private issuer in the pharmaceutical sector, Pharvaris N.V. is subject to SEC regulations for its 20-F filings and ongoing disclosure requirements. Compliance with Good Manufacturing Practices (GMP) and other health authority regulations (e.g., FDA, EMA) is critical for its product development and commercialization efforts, posing potential risks if not met.

What Investors Should Do

1. [object Object]
2. [object Object]

Key Dates

• 2025-12-31: Fiscal Year End — Marks the end of the reporting period for the 20-F filing.
• 2026-04-02: Filing Date — Indicates when the annual report was submitted to the SEC, providing a timeline for regulatory compliance.

Glossary

20-F

An annual report required by the U.S. Securities and Exchange Commission (SEC) for foreign private issuers, containing comprehensive information about the company's business, financial condition, and management. (This is the primary document being analyzed, providing the structural framework for Pharvaris N.V.'s disclosures.)

CIK

Central Index Key, a unique identifier assigned to each entity that files with the SEC. (Essential for tracking all filings and information related to Pharvaris N.V. on the SEC's EDGAR system.)

SIC Code

Standard Industrial Classification code, used to classify industries and businesses. (Identifies Pharvaris N.V. as operating within the Pharmaceutical Preparations industry (SIC 2834).)

iXBRL

Inline eXtensible Business Reporting Language, a standard for digital financial reporting that embeds XBRL data directly into HTML documents. (Indicates that the 20-F filing includes machine-readable financial data, facilitating automated analysis.)

Year-Over-Year Comparison

This analysis is based on the 20-F filing for the period ending December 31, 2025. As this is a structural document and specific financial performance data for revenue, net income, or margins is not provided, a direct comparison to a previous filing regarding these metrics is not possible. The filing confirms the company's status as a foreign private issuer and its industry classification (SIC 2834), but lacks comparative operational or financial changes.

From the Filing

EDGAR Filing Documents for 0001830487-26-000013 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: SEC Accession No. 0001830487-26-000013 Filing Date 2026-04-02 Accepted 2026-04-02 06:51:25 Documents 124 Period of Report 2025-12-31 Interactive Data Document Format Files Seq Description Document Type Size 1 20-F phvs-20251231.htm iXBRL 20-F 5483640 2 EX-2.1 phvs-ex2_1.htm EX-2.1 204630 3 EX-8.1 phvs-ex8_1.htm EX-8.1 9257 4 EX-11.1 phvs-ex11_1.htm EX-11.1 78910 5 EX-12.1 phvs-ex12_1.htm EX-12.1 14900 6 EX-12.2 phvs-ex12_2.htm EX-12.2 14332 7 EX-13.1 phvs-ex13_1.htm EX-13.1 5284 8 EX-13.2 phvs-ex13_2.htm EX-13.2 5271 9 EX-15.1 phvs-ex15_1.htm EX-15.1 4917 10 EX-97.1 phvs-ex97_1.htm EX-97.1 38479 11 GRAPHIC img22554315_0.gif GRAPHIC 75494 12 GRAPHIC img22554315_1.gif GRAPHIC 53825 13 GRAPHIC img22554315_2.gif GRAPHIC 42732 14 GRAPHIC img22554315_3.gif GRAPHIC 18856 15 GRAPHIC img22554315_4.gif GRAPHIC 66479 16 GRAPHIC img22554315_5.gif GRAPHIC 33295 17 GRAPHIC img22554315_6.jpg GRAPHIC 63274 18 GRAPHIC img22554315_7.jpg GRAPHIC 189721 19 GRAPHIC img22554315_8.gif GRAPHIC 34696 20 GRAPHIC img22554315_9.gif GRAPHIC 22160 21 GRAPHIC img22554315_10.gif GRAPHIC 42137 22 GRAPHIC img22554315_11.gif GRAPHIC 55427 23 GRAPHIC img22554315_12.gif GRAPHIC 43934 24 GRAPHIC img22554315_13.gif GRAPHIC 44315 25 GRAPHIC img22554315_14.gif GRAPHIC 33948 26 GRAPHIC img22554315_15.jpg GRAPHIC 109873 27 GRAPHIC img22554315_16.jpg GRAPHIC 78320 28 GRAPHIC img22554315_17.jpg GRAPHIC 119532 Complete submission text file 0001830487-26-000013.txt 18511252 Data Files Seq Description Document Type Size 29 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT phvs-20251231.xsd EX-101.SCH 1381036 127 EXTRACTED XBRL INSTANCE DOCUMENT phvs-20251231_htm.xml XML 2966956 Mailing Address J.H. OORTWEG 21 2333 CH LEIDEN LEIDEN Netherlands Business Address J.H. OORTWEG 21 2333 CH LEIDEN LEIDEN Netherlands 31 (0)71 203 6410 Pharvaris N.V. (Filer) CIK : 0001830487 (see all company filings) EIN. : 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231 Type: 20-F | Act: 34 | File No.: 001-40010 | Film No.: 26830568 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)